- Home
- PEGA vs ERAS Comparison
PEGA vs ERAS Comparison
Compare PEGA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | ERAS |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PEGA | ERAS |
|---|---|---|
| Price | $36.14 | $10.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $60.13 | $14.25 |
| AVG Volume (30 Days) | 2.5M | ★ 8.7M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 91.89 | 36.23 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $682,695,000.00 | N/A |
| Revenue This Year | $15.99 | N/A |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | $197.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.34 | $1.06 |
| 52 Week High | $105.50 | $24.28 |
Technical Indicators
Market Signals| Indicator | PEGA | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 34.19 |
| Support Level | $35.11 | $1.98 |
| Resistance Level | $44.95 | $17.17 |
| Average True Range (ATR) | 2.20 | 2.12 |
| MACD | -0.47 | -1.30 |
| Stochastic Oscillator | 17.45 | 12.32 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.